Amarendra Pegu

List of Publications by Year in Descending Order

61 papers	4,089 citations	31 h-index	63 g-index
65 ext. papers	5,447 ext. citations	14.7 avg, IF	4.75 L-index

#	Paper	IF	Citations
61	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.. *Cell Reports*, **2022**, 38, 110199	10.6	3
60	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. **2022**,		1
59	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.. *Science*, **2022**, 376, eabn8897	33.3	18
58	Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. **2022**,		1
57	Broadly neutralizing antibodies target the coronavirus fusion peptide. **2022**,		3
56	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. *Cell Reports*, **2021**, 35, 108937	10.6	1
55	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants **2021**,		6
54	Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues. *Journal of Immunology*, **2021**, 207, 505-511	5.3	0
53	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. *Science*, **2021**, 373,	33.3	80
52	Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques. *PLoS Pathogens*, **2021**, 17, e1009738	7.6	3
51	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. *MAbs*, **2021**, 13, 1946918	6.6	1
50	TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. *PLoS Pathogens*, **2021**, 17, e1009339	7.6	11
49	Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. *JCI Insight*, **2021**, 6,	9.9	4
48	Blocking 4integrin delays viral rebound in SHIV-infected macaques treated with anti-HIV broadly neutralizing antibodies. *Science Translational Medicine*, **2021**, 13,	17.5	2
47	Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *New England Journal of Medicine*, **2021**, 385, 664-666	59.2	137
46	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. *Science Translational Medicine*, **2021**, 13, eabj5413	17.5	18
45	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science*, **2021**, 373, 1372-1377	33.3	150

44	Anti-HIV-1 Antibodies: An Update. *BioDrugs*, **2020**, 34, 121-132	7.9	5
43	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. *Journal of Clinical Investigation*, **2020**, 130, 3299-3304	15.9	9
42	A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone **2020**,		2
41	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. *Nature Communications*, **2020**, 11, 70	17.4	21
40	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 18754-18763	11.5	28
39	Removal of variable domain -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. *MAbs*, **2020**, 12, 1836719	6.6	3
38	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *New England Journal of Medicine*, **2020**, 383, 1544-1555	59.2	612
37	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. *Scientific Reports*, **2020**, 10, 18149	4.9	41
36	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. *Cell Host and Microbe*, **2019**, 26, 336-346.e3	23.4	43
35	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. *Lancet HIV,the*, **2019**, 6, e667-e679	7.8	33
34	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. *PLoS Pathogens*, **2019**, 15, e1007632	7.6	9
33	Delayed vaginal SHIV infection in VRC01 and anti-4 treated rhesus macaques. *PLoS Pathogens*, **2019**, 15, e1007776	7.6	11
32	Improvement of antibody functionality by structure-guided paratope engraftment. *Nature Communications*, **2019**, 10, 721	17.4	17
31	Bispecific antibodies: Potential immunotherapies for HIV treatment. *Methods*, **2019**, 154, 118-124	4.6	12
30	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. *Cell Reports*, **2018**, 22, 1798-1809	10.6	33
29	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. *Human Vaccines and Immunotherapeutics*, **2018**, 14, 2116-2127	4.4	14
28	Glycoengineering HIV-1 Env creates superchargedand hybridaglycans to increase neutralizing antibody potency, breadth and saturation. *PLoS Pathogens*, **2018**, 14, e1007024	7.6	12
27	Accumulation of follicular CD8+ T cells in pathogenic SIV infection. *Journal of Clinical Investigation*, **2018**, 128, 2089-2103	15.9	31

26	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. *Science Translational Medicine*, **2017**, 9,	17.5	106
25	Use of broadly neutralizing antibodies for HIV-1 prevention. *Immunological Reviews*, **2017**, 275, 296-312	11.3	101
24	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. *Journal of Virology*, **2017**, 91,	6.6	32
23	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. *Science*, **2017**, 358, 85-90	33.3	176
22	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. *Science Translational Medicine*, **2017**, 9,	17.5	65
21	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. *Journal of Virology*, **2017**, 91,	6.6	27
20	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. *Nature Medicine*, **2016**, 22, 362-8	50.5	134
19	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. *Journal of Virology*, **2016**, 90, 1321-32	6.6	57
18	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. *Journal of Virology*, **2016**, 90, 76-91	6.6	151
17	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. *Nature*, **2016**, 533, 105-109	50.4	229
16	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. *Journal of Virology*, **2016**, 90, 5899-5914	6.6	45
15	Eliminating antibody polyreactivity through addition of N-linked glycosylation. *Protein Science*, **2015**, 24, 1019-30	6.3	8
14	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. *Journal of Virology*, **2015**, 89, 5895-903	6.6	82
13	Activation and lysis of human CD4 cells latently infected with HIV-1. *Nature Communications*, **2015**, 6, 8447	17.4	73
12	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. *Journal of Virology*, **2015**, 89, 12501-12	6.6	67
11	Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. *Clinical and Experimental Immunology*, **2015**, 182, 289-301	6.2	177
10	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. *Journal of Virology*, **2014**, 88, 12669-82	6.6	198
9	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. *Nature*, **2014**, 514, 642-5	50.4	232

8	B-108 Germinal center CD8 T cells can be redirected to eliminate HIV-expressing T follicular helper cells. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2014**, 67, 47	3.1	
7	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. *Science Translational Medicine*, **2014**, 6, 243ra88	17.5	189
6	P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection. *Retrovirology*, **2009**, 6,	3.6	78
5	P13-07 LB. A human blocking antibody to CCR5 partially protects against lentiviral infection in non-human primates. *Retrovirology*, **2009**, 6,	3.6	78
4	Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. *Journal of Virology*, **2008**, 82, 4793-806	6.6	108
3	Human lymphatic endothelial cells express multiple functional TLRs. *Journal of Immunology*, **2008**, 180, 3399-405	5.3	89
2	Afferent and efferent interfaces of lymph nodes are distinguished by expression of lymphatic endothelial markers and chemokines. *Lymphatic Research and Biology*, **2007**, 5, 91-103	2.3	16
1	Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. *Infection and Immunity*, **2006**, 74, 3790-803	3.7	189